Phase 1: To determine the recommended phase 2 dose (RP2D) of vorinostat in children, adolescents and young adults following allogeneic HCT. Phase 2: To determine the incidence of grade 2‐4 acute GVHD by day +100 in subjects who receive vorinostat in addition to standard GVHD prophylaxis after allogeneic BMT.
This is a prospective phase 1/2 trial designed to assess the hypothesis that vorinostat, in addition to standard graft versus host disease (GVHD) prophylaxis, is feasible and safe in children, adolescent and young adult patients. All subjects will undergo allogeneic BMT according to local site institutional practice.
Patients 3 years to 39 years of age undergoing allogeneic BMT for malignant hematologic disease. Please contact study team for additional information.
Principal Investigator